Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CD83 Biologics Sequence Review Report 2026: CD83 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD83 Biologics Sequence Review Report 2026: CD83 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD83 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD82 Biologics Sequence Review Report 2026: CD82 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD82 Biologics Sequence Review Report 2026: CD82 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD82 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD81 Biologics Sequence Review Report 2026: CD81 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD81 Biologics Sequence Review Report 2026: CD81 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD81 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD74 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen gamma chain Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD74 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen gamma chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD74 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD72 Biologics Sequence Review Report 2026: B-cell differentiation antigen CD72 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD72 Biologics Sequence Review Report 2026: B-cell differentiation antigen CD72 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD72 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD63 Biologics Sequence Review Report 2026: CD63 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD63 Biologics Sequence Review Report 2026: CD63 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD63 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD5L Biologics Sequence Review Report 2026: CD5 antigen-like Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD5L Biologics Sequence Review Report 2026: CD5 antigen-like Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD5L protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD58 Biologics Sequence Review Report 2026: Lymphocyte function-associated antigen 3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD58 Biologics Sequence Review Report 2026: Lymphocyte function-associated antigen 3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD58 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD37 Biologics Sequence Review Report 2026: Leukocyte antigen CD37 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD37 Biologics Sequence Review Report 2026: Leukocyte antigen CD37 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD37 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD34 Biologics Sequence Review Report 2026: Hematopoietic progenitor cell antigen CD34 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD34 Biologics Sequence Review Report 2026: Hematopoietic progenitor cell antigen CD34 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD34 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD320 Biologics Sequence Review Report 2026: CD320 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD320 Biologics Sequence Review Report 2026: CD320 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD320 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD302 Biologics Sequence Review Report 2026: CD302 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD302 Biologics Sequence Review Report 2026: CD302 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD302 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →